Abstract
Active surveillance cultures and contact precautions is a strategy to control the transmission of methicillin-resistant Staphylococcus aureus (MRSA) within healthcare facilities. Whether to implement this strategy to routinely screen and isolate inpatients with MRSA in non-outbreak (endemic) settings, or to remove it and use standard infection control precautions only is scientifically and ethically controversial, in view of the potential adverse effects of contact precautions on patients. To support the use of standard precautions only, it has been argued that active surveillance to identify patients who are asymptomatically colonised with MRSA to place them in contact precautions is unjust or unfair to these patients in various ways. This paper will unpack and examine four distinct arguments, which are advanced from a medical ethics or quality improvement ethical framework, for why this is so. Our analysis shows that while these arguments highlight the injustice of current practices, they do not provide strong ethical reasons for justifying the removal of active surveillance and contact precautions to control MRSA transmission and infection. An implication of our arguments is that the ethical frame for evaluating prevention and control strategies for MRSA, a multi-drug resistant bacteria, should shift from healthcare to primarily public health. From a public health ethics perspective, whether a strategy is unjust, or how ethically significant its lack of fairness is, depends on assessing the evidence for its public health effectiveness and necessity in a given setting, and the extent of the harms and burdens patients with MRSA bear when they are on contact precautions, which remain matters of scientific debate or uncertainty. As an ethical consideration in the debate, the chief normative implication of justice is to provide us further reasons to revise current active surveillance-contact precautions practices, and for the need for research and interventions to minimise their potential adverse effects on patients.
Similar content being viewed by others
References
Abbas, S. & Stevens, M. (2018). Guide to infection control in the healthcare setting: Horizontal vs vertical infection control strategies. Retrieved August 8, 2019, from International Society for Infectious Diseases website: https://www.isid.org/guide/horizontal-vs-vertical-infection-control-strategies/
Andersson, H., C. Lindholm, and B. Fossum. 2011. MRSA—global threat and personal disaster: Patients’ experiences. International Nursing Review 58: 47–53.
Braut, G.S., and J. Holt. 2011. Methicillin-resistant Staphylococcus aureus infection—the infectious stigma of our time? Journal of Hospital Infection 77: 148–152.
Choo, E.J. 2017. Community-associated methicillin-resistant Staphylococcus aureus in nosocomial infections. Infection & Chemotherapy 49: 158–159.
Cohen, C., B. Cohen, and J. Shang. 2015. Effectiveness of contact precautions against multidrug-resistant organism transmission in acute care: A systematic review of the literature. Journal of Hospital Infection 90: 275–284.
Criddle, P., and J. Potter. 2006. Exploring patients' views on colonisation with meticillin-resistant Staphylococcus aureus. Journal of Infection Prevention 7: 24–28.
David, M.Z., and R.S. Daum. 2010. Community-associated methicillin-resistant Staphylococcus aureus: Epidemiology and clinical consequences of an emerging epidemic. Clinical Microbiology Reviews 23: 616–687.
Edmond, M., L. Lyckholm, and D. Diekema. 2008. Ethical implications of active surveillance cultures and contact precautions for controlling multidrug resistant organisms in the hospital setting. Public Health Ethics 1: 235–245.
Edmond, M.B., and R.P. Wenzel. 2013. Screening inpatients for MRSA—Case closed. The New England Journal of Medicine 2013 (368): 2314–2315.
Goldsack, J.C., et al. 2014. Clinical, patient experience and cost impacts of performing active surveillance on known methicillin-resistant Staphylococcus aureus positive patients admitted to medical-surgical units. American Journal of Infection Control 42: 1039–1043.
Gordon, R.J., and F.G. Lowy. 2008. Pathogenesis of methicillin-resistant Staphylococcus aureus Infection. Clinical Infectious Diseases 46: S350–S359.
Harris, J., K. Walsh, and S. Dodds. 2019. Are contact precautions ethically justifiable in contemporary hospital care? Nursing Ethics 26: 611–624.
Hsu, L.Y. 2015. Evolutionary dynamics of methicillin-resistant Staphylococcus aureus within a healthcare system. Genome Biology 16: 81.
Huang, S.S., et al. 2013. Targeted versus universal decolonization to prevent ICU infection. New England Journal of Medicine 368: 2255–2265.
Humphreys, H., et al. 2009. Prevention and control of methicillin-resistant Staphylococcus aureus. Clinical Microbiology and Infection 5: 120–124.
IPACT. 2015. Policy for the screening of patients for meticillin resistant Staphylococcus aureus (MRSA) and treatment and management of MRSA positive patients. Retrieved August 8, 2019, from NHS Foundation Trust, Queen Victoria Hospital website. https://www.qvh.nhs.uk/wp-content/uploads/2015/09/Management-and-Screening-of-patients-with-MRSA-2015.pdf
Kampf, G. 2016. Acquired resistance to chlorhexidine—is it time to establish an 'antiseptic stewardship' initiative? The Journal of Hospital Infection 94: 213–227.
Kavanagh, K.T. 2019. Control of MSSA and MRSA in the United States: Protocols, policies, risk adjustment and excuses. Antimicrobial Resistance and Infection Control, 8 (103).
Kirkland, K.B. 2010. From best to good: Can we ‘Right-Size’ approaches to reducing healthcare-associated infections? Infection Control & Hospital Epidemiology 31: 784–785.
Landelle, C., L. Pagani, and S. Harbarth. 2013. Is patient isolation the single most important measure to prevent the spread of multidrug-resistant pathogens? Virulence 4: 163–171.
Lin, M.Y., et al. 2018. Regional Epidemiology of methicillin-resistant Staphylococcus aureus among adult intensive care unit patients following state-mandated active surveillance. Clinical Infectious Diseases 66: 1535–1539.
Lupión-Mendoza, C., et al. 2015. Effects of isolation on patients and staff. American Journal of Infection Control 43: 397–399.
Magill, S.S. 2014. Multistate point-prevalence survey of health care–associated infections. New England Journal of Medicine 370: 1198–1208.
Ministry of Health, Singapore (2013). Guidelines For control and prevention of multi-drug resistant organisms (MDROS) in healthcare facilities. Retrieved August 8, 2019, from Ministry of Health, Singapore website. https://www.moh.gov.sg/docs/librariesprovider5/resources-statistics/guidelines/guidelines-for-control-and-prevention-of-multi-drug-resistant-organisms-(mdros)-in-healthcare-facilities---nov-2013.pdf
Morgan, D.J., et al. 2009. Adverse outcomes associated with contact precautions: A review of the literature. American Journal of Infection Control 37: 85–93.
Morgan, J.M., K.S. Kaye, and D.J. Diekema. 2014. Reconsidering isolation precautions for endemic methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus. JAMA 312: 1395–1396.
Mozzillo, K.L., N. Ortiz, and L.G. Miller. 2010. Patients with methicillin-resistant Staphylococcus aureus infection: twenty-first century lepers. Journal of Hospital Infections 75: 132–134.
Peterson, L.R., and D.J. Diekema. 2010. To screen or not to screen for methicillin-resistant Staphylococcus aureus. Journal of Clinical Microbiology 48: 683–689.
Reynolds, C., et al. 2014. Are nursing homes less likely to admit methicillin-resistant Staphylococcus aureus carriers? American Journal of Infection Control 42: 63–65.
Richey, L.E. 2017. When should contact precautions be discontinued for patients with methicillin-resistant Staphylococcus aureus? American Journal of Infection Control 45: 75–76.
Rump, B., et al. 2017. Signs of stigma and poor mental health among carriers of MRSA. Journal of Hospital Infection 95: 268–274.
Rump, B., et al. 2018. Ethics of infection control measures for carriers of antimicrobials drug-resistant organisms. Emerging Infectious Diseases 24: 1609–1616.
Santos, R.P., T.W. Mayo, and J.D. Siegel. 2008. Active surveillance cultures and contact precautions for control of multidrug-resistant organisms: Ethical considerations. Clinical Infectious Diseases 47: 110–116.
Sengupta, A., et al. 2011. Knowledge, awareness and attitudes regarding methicillin-resistant Staphylococcus aureus among caregivers of hospitalized children. Journal of Pediatrics 158: 416–421.
Shenoy, E.S., et al. 2014. Natural history of colonization with methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE): A systematic review. BMC Infectious Diseases 14: 177.
Siegel, J.D., et al. 2007. Management of multidrug-resistant organisms in health care settings, 2006. American Journal of Infection Control 35: S165–S193.
Stelfox, H., D.W. Bates, and D.A. Redelmeier. 2003. Safety of patients isolated for infection control. JAMA 290: 1899–1905.
Stevens, D.L. 2015. Infections of the skin, muscles, and soft tissues. In Harrison’s Principles of Internal Medicine, ed. Kasper, D., Fauci, A., Hauser, S., Longo, D., Jameson, J.L. & Loscalzo J., 156–157, 19th edn. New York: McGraw Hill.
Tarzi, S., et al. 2001. Methicillin-resistant Staphylococcus aureus: Psychological impact of hospitalization and isolation in an older adult population. Journal of Hospital Infection 49: 250–254.
Weber, S.G., et al. 2007. Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: Position statement from the Joint SHEA and APIC Task Force. American Journal of Infection Control 35: 73–85.
Weiner, L.M., et al. 2016. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the national healthcare safety network at the Centers for Disease Control and Prevention, 2011–2014. Infection Control and Hospital Epidemiology 37: 1288–1301.
Acknowledgements
Teck Chuan Voo’s contribution was funded by a NUS start-up Grant (R-171-000-060-133) and a short-term fellowship from the Singapore Infectious Diseases Initiative. We would like to acknowledge Clarence Tam and Paul Tambyah for their helpful input on the clinical, public health and ethical aspects of MRSA prevention and control. We would also like to thank the anonymous reviewers for their comments and suggestions which greatly improved the quality of the paper.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Voo, T.C., Lederman, Z. Justice in control of methicillin-resistant Staphylococcus aureus transmission: a fair question to ask?. Monash Bioeth. Rev. 38 (Suppl 1), 56–71 (2020). https://doi.org/10.1007/s40592-020-00109-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40592-020-00109-x